CytoMed Therapeutics (NASDAQ:GDTC) Stock Rating Reaffirmed by Benchmark

Benchmark reissued their speculative buy rating on shares of CytoMed Therapeutics (NASDAQ:GDTC) in a research note published on Thursday morning, Marketbeat reports. They currently have a $5.00 target price on the stock.

CytoMed Therapeutics Price Performance

NASDAQ GDTC opened at $2.04 on Thursday. The company has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $1.91. CytoMed Therapeutics has a 12-month low of $1.20 and a 12-month high of $5.50.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.